QED Therapeutics Revenue and Competitors

Location

$65M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • QED Therapeutics's estimated annual revenue is currently $3.4M per year.(i)
  • QED Therapeutics received $65.0M in venture funding in January 2018.
  • QED Therapeutics's estimated revenue per employee is $77,500
  • QED Therapeutics's total funding is $65M.

Employee Data

  • QED Therapeutics has 44 Employees.(i)
  • QED Therapeutics grew their employee count by 0% last year.

QED Therapeutics's People

NameTitleEmail/Phone
1
SVP, Pharmaceutical Development, QED TherapeuticsReveal Email/Phone
2
VP Global Medical AffairsReveal Email/Phone
3
DirectorReveal Email/Phone
4
Director, Clinical OperationsReveal Email/Phone
5
Associate Director, Quality AssuranceReveal Email/Phone
6
Associate Director Quality AssuranceReveal Email/Phone
7
Director, Pharmaceutical DevelopmentReveal Email/Phone
8
Executive DirectorReveal Email/Phone
9
Associate Director Scientific CommunicationsReveal Email/Phone
10
Executive Director Clinical Quality AssuranceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is QED Therapeutics?

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.

keywords:N/A

$65M

Total Funding

44

Number of Employees

$3.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

QED Therapeutics News

2022-04-17 - HER2 negative Breast Cancer Pipeline Insights | Research Report 2022 by DelveInsight

... HER2 negative Breast Cancer treatment therapies, as per DelveInsight ... QED Therapeutics, Inc., Tyme, Inc., PIQUR Therapeutics, Pfizer,...

2019-09-05 - BridgeBio Launches New Subsidiary to Tackle Limb-Girdle ...

Sarepta Therapeutics is also focused on the disease. ... comes about a year after BridgeBio launched QED Therapeutics to develop infigratinib, ...

2019-06-03 - QED Therapeutics Presents New Data on the Potential for ...

SAN FRANCISCO, June 3, 2019 /PRNewswire/ -- QED Therapeutics announced today the presentation of data demonstrating the clinical ...

2019-04-01 - Preclinical Data Demonstrates the Potential of QED ...

SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- QED Therapeutics announced today the presentation of preclinical data demonstrating the ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.8M44-15%N/A
#2
$6.3M44-8%N/A
#3
$5.4M44159%$8M
#4
$6.2M442%N/A
#5
$6.8M4452%$28M

QED Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-01-31$65.0MUndisclosedBridgeBio PharmaArticle